Key points from article :
Five Alarm Bio has emerged through a seed round which will put its anti-ageing agenda into clinical trials mode.
It is progressing with a therapeutic program in sarcopenia and potential treatment for neurodegenerative diseases such as Alzheimer’s.
Janette Thomas, CEO explains:
“Five Alarm Bio was started by three entrepreneurs in 2016, did the early research then didn’t have any funding then got the grant that kickstarted everything.”
“In March we collaborated with Magnitude Biosciences to test its technology in the worm C. elegans, showing a 40 percent increase in healthspan.”
The clinical trials are based on a small molecule approach to boost the body’s defense against aging, based on a new understanding of how the chemical damage associated with age accumulates in cells.
"We’re not looking to cure ageing but to give people a healthy lifespan.”
“The seed round – we’re raising up to £600k and so far have got more than half of that – would give us two years’ money".
The research is carried out at Babraham Research Campus.
